The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 801–900 of 1,000
Fenofibrate and diabetic retinopathy
Kartı, Ö., & Saatçi, A. O. (2024) · Medical Hypothesis Discovery & Innovation in Ophthalmology · doi:10.51329/mehdiophthal1492 · Cited by 7
Wu, Y., Hsu, C., Hwang, S., Lin, K., Lin, P.-C., Huang, Y., Lee, C., Chang, C.-I., & Huang, M. (2024) · Nutrients · doi:10.3390/nu16142274 · Cited by 9
Fenofibrate and Diabetic Retinopathy
Parra-Pineda, A., Lizarazo-Bocanegra, S., Villalba-Montero, L. F., Ayala-Quintero, C. C., Losada-Díaz, F., Correa-Osio, I., Lizarazo-Rojas, L. A., & Mendivil, C. O. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01774-z · Cited by 8
Yamaji, T., Harada, T., Hashimoto, Y., Takaeko, Y., Kajikawa, M., Han, Y., Maruhashi, T., Kishimoto, S., Hashimoto, H., Kihara, Y., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045415 · Cited by 6
Primary Health Care in Pandemics: Barriers, Challenges and Opportunities
Khoja, T. A. M., Qidwai, W., Rawaf, S., Alnasir, F. A., Nanji, K., Khoja, A. T., Kurashi, N. Y. A., Saad, N. E. S., Halasa, W., Farahat, T. M., et al. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94090 · Cited by 7
Zhang, C., Lin, W., Xu, Q., Li, H., Xu, C., Ma, X., Hao, M., & Kuang, H. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108471 · Cited by 7
Reevaluating Goals of Insulin Therapy: Perspectives from Large Clinical Trials
Riddle, M. C., & Yuen, K. C. J. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.003 · Cited by 7
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13207 · Cited by 8
Telemedicine and diabetic retinopathy
DeTore, J., & Rizzolo, D. (2018) · JAAPA · doi:10.1097/01.jaa.0000544310.25116.97 · Cited by 7
Use of Fenofibrate in the Management of Diabetic Retinopathy—Large Population Analyses
Frank, R. N. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.0634 · Cited by 7
Cheng, L. Z., Gai, Z., Zhou, Y., Lu, X., Zhang, F., Ye, H., & Duan, J. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/762783 · Cited by 7
Modern approach to early diagnosis and pathogenetic treatment of diabetic retinopathy
Воробьева, И. В. (2016) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2016132560-67 · Cited by 7
Xu, L., Brown, E. E., Santiago, C. P., Keuthan, C. J., Lobanova, E. S., & Ash, J. D. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101700 · Cited by 7
Epidemiology, Risk Factors, and Pathophysiology of Diabetic Retinopathy
Bhagat, N., & Zarbin, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96157-6_1 · Cited by 7
‘Hard,’ ‘soft’ and ‘surrogate’ endpoints in diabetes
Yudkin, J. S., & Eggleston, E. (2012) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2012-201361 · Cited by 7
Bulum, T., Tomić, M., & Duvnjak, L. S. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.10.003 · Cited by 7
Kawamura, T., Sato, I., Tamura, H., Nakao, Y. M., & Kawakami, K. (2017) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-017-0551-8 · Cited by 7
What is new in lipid‐lowering therapies in diabetes?
Cheung, Y.-M. M., O’Brien, R., & Ekinci, E. I. (2019) · Internal Medicine Journal · doi:10.1111/imj.14291 · Cited by 7
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.007 · Cited by 7
Tatsumi, T., Takatsuna, Y., Ishibashi, R., Koshizaka, M., Kaiho, T., Oshitari, T., Shiko, Y., Asaumi, N., Yamamoto, S., Yokote, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16636 · Cited by 6
Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges
Du, J. L., & Ronco, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104496 · Cited by 7
Toth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 7
Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
Davis, T. M. E. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.927647 · Cited by 6
Zhang, F., Xu, W., Deng, Z., & Huang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1487981 · Cited by 6
Li, M., Wang, F., Wang, X., Zang, Y., Liu, W., Wang, F., Zhang, L., Tang, Q., Liu, S., & Zhao, D. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0004 · Cited by 6
Pleiotropic effects of PPAR-α – from benchside to bedside
Shirinsky, I. V., & Shirinsky, V. S. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-peo-2222 · Cited by 6
Reduced macula microvascular densities may be an early indicator for diabetic peripheral neuropathy
Deng, X., Wang, S., Yang, Y., Chen, A., Lu, J., Hao, J., Wu, Y., & Lu, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1081285 · Cited by 6
Sada, K., Yoshida, Y., Shibuta, K., Kimoto, K., Miyamoto, S., Ozeki, Y., Okamoto, M., Gotoh, K., Masaki, T., Yokoyama, K., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad358 · Cited by 6
Loukovaara, S., Korhonen, A., NISKANEN, L. K., & Haukka, J. K. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15778 · Cited by 6
Nussbaumerová, B., Rosolová, H., Mayer, O., Filipovský, J., Cífková, R., & Bruthans, J. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.02.002 · Cited by 6
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
Katz, P. M., & Leiter, L. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.017 · Cited by 6
Diabetes and Diabetic Retinopathy: Overview of a Worldwide Epidemic
Stewart, M. W. (2017) · Springer eBooks · doi:10.1007/978-981-10-3509-8_1 · Cited by 6
Rahman, S. M., Nawaz, R., Khan, G. J., & Aamir, A. H. (2011) · PubMed · Cited by 6
Diabetic dyslipidemia and microvascular complications of diabetes
Karásek, D., & Vaverková, H. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.003 · Cited by 6
Anterior Diabetic Retinopathy Studied by Ultra-widefield Angiography
Bae, K., Lee, J., Kim, T. H., Cho, H. J., Ahn, J., Kim, S. J., Kim, J. H., & Kang, S. W. (2016) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2016.30.5.344 · Cited by 6
Progression of Diabetic Retinopathy in the Hypertension Intervention Nurse Telemedicine Study
Muir, K. W., Grubber, J. M., Mruthyunjaya, P., McCant, F., & Bosworth, H. B. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.81 · Cited by 6
Han, J., Yu, H., Tu, Y., Pang, J., Liu, F., Bao, Y., Yang, W., & Jia, W. (2016) · Diabetic Medicine · doi:10.1111/dme.13154 · Cited by 6
Atalay, H., Böyük, B., Değirmencioğlu, Ş., Güzel, S., Çelebi, A., & Ekizoğlu, İ. (2015) · Istanbul Medical Journal · doi:10.5152/imj.2015.05902 · Cited by 6
Fibrate use in diabetes: New concepts
Bloomgarden, Z. T., & Drexler, A. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00108.x · Cited by 6
Treat-to-Target in Axial Spondyloarthritis: Are we there yet?
Aouad, K., & Elzorkany, B. K. (2022) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.33.1.137 · Cited by 6
Early diagnostic of diabetic foot using thermal images
Cajacuri, L. A. V. (2013) · theses.fr (ABES) · doi:10.70675/a22bf653zda6fz4a91zbd90z2f11c7afabe4 · Cited by 10
Papadopoulos, N., Arvaniti, E., Angelopoulos, T. P., Τζιόμαλος, Κ., Tembra, M. S., Díaz-Díaz, J. L., Niet, S. D., Silva, S. D., & Doupis, J. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70047 · Cited by 5
Xu, J., Chen, S., Sun, M., Chen, X., Gu, Z., Zhang, Y., Xie, L., & Hao, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07353-x · Cited by 5
Hunfeld, E., Tayar, A., Paúl, S., Poschkamp, B., Großjohann, R., Morawiec-Kisiel, E., Bohl, B., Pfeil, J. M., Busch, M., Dähmcke, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-36970-9 · Cited by 5
Sugawa, S. W., Yoshida, Y., Hikima, Y., Sato, H., Shimada, A., Noda, M., & Kushiyama, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/7572326 · Cited by 5
Thaker, S., Kumar, V., Singh, U., & Kumar, S. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1294_22 · Cited by 5
Larose, S., Filliter, C., Platt, R. W., Yu, O. H. Y., & Filion, K. B. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15106 · Cited by 6
Fenofibrate and renal disease: clinical effects in diabetes
Ting, R.-D., & KEECH, A. C. (2013) · Clinical Lipidology · doi:10.2217/clp.13.69 · Cited by 5
Complicaciones microvasculares de la diabetes
García-Ocaña, P., Cobos-Palacios, L., & Martínez, L. F. C. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.012 · Cited by 5
Aldafas, R., Crabtree, T. S. J., Vinogradova, Y., Gordon, J. P., & IDRIS, I. R. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166489 · Cited by 5
Design, recruitment and baseline characteristics of the LENS trial
The LENS Collaborative Group (2024) · Diabetic Medicine · doi:10.1111/dme.15310 · Cited by 5
Self-citationJeong, H., Shaia, J. K., Talcott, K. E., & Singh, R. P. (2024) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20240729-03 · Cited by 5
Chang, C., & Chuang, L. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00085.x · Cited by 5
Frontoni, S., Solini, A., Fioretto, P., Natali, A., Zuccalà, A., Cosentino, F., & Penno, G. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.01.004 · Cited by 5
Sight-threatening diabetic eye disease: an update and review of the literature
Symes, R. J., Liew, G., & Tufail, A. (2014) · British Journal of General Practice · doi:10.3399/bjgp14x682033 · Cited by 5
Antihypertensive Drugs and Diabetic Retinopathy in Patients with Type 2 Diabetes
Lin, J.-C., & Lai, M. (2015) · Ophthalmologica · doi:10.1159/000441958 · Cited by 5
Akiyode, O., & Tran, C. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.1.44 · Cited by 5
Basic Mechanisms of Pathological Retinal and Choroidal Angiogenesis
Vavvas, D. G., & Miller, J. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00026-6 · Cited by 5
Chiquete, E., & Lavalle-Gonzalez, F. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s107437 · Cited by 5
Terapia con fibratos: uso racional del fenofibrato 2016. Resumen ejecutivo
Brea, Á., Millán, J., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.06.001 · Cited by 5
Diabetic Retinopathy and Antivascular Endothelial Growth Factor Agents
Patel, S. N., & Sternberg, P. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.0318 · Cited by 5
An Overview of Diabetic Retinopathy
Nakao, S., Yoshida, S., & Sonoda, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00011-8 · Cited by 5
Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema
Rahimy, E., Baker, K., Thompson, D. E., Saroj, N., & On behalf of the VIVID and VISTA Study Investigators (2020) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20200326-04 · Cited by 5
Hasan, D. M. A., Islam, S. M. R., & Azad, D. M. A. K. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101219 · Cited by 5
Fenofibrate for Treating Diabetic Eye Disease
Simó, R., & Hernández, C. (2023) · Diabetes · doi:10.2337/dbi22-0037 · Cited by 5
Diabetic Retinopathy – Diagnostics and Treatment Guidelines
Studnička, J., Němčanský, J., Vysloužilová, D., Ernest, J., & Němec, P. (2023) · Czech and Slovak Ophthalmology · doi:10.31348/2023/28 · Cited by 5
Garoon, R. B., Coffee, R. E., Jiang, L., Weng, C. Y., & Carvounis, P. E. (2016) · Journal of Ophthalmology · doi:10.1155/2016/5282470 · Cited by 5
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00562-5 · Cited by 5
Shahi, N., & Tobe, S. W. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.052 · Cited by 5
Brea, Á., Millán, J., Ascaso, J. F., Blasco, M., Díaz, A., Hernández‐Mijares, A., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.06.002 · Cited by 5
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 5
Yu, Q., Wang, F., Zhou, L., Yang, J., Liu, K., & Xu, X. (2020) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20200129-05 · Cited by 5
Shotliff, K., & Davies, N. (2010) · Diabetes · doi:10.1002/9781118405550.ch1 · Cited by 5
Fenofibrate and diabetic retinopathy
Fagan, X. J., & Chong, E. W. T. (2015) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12539 · Cited by 5
Diabetic retinopathy: A global epidemic
Das, A. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.154385 · Cited by 5
The role of dyslipidemia in diabetic retinopathy: A brighter focus?
Jialal, I., Rajamani, U., & Siegel, D. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.07.002 · Cited by 5
Toward Optimal Screening for Diabetic Retinopathy: Balancing Precision and Pragmatism
Barkmeier, A. J. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.008 · Cited by 5
Customizing AI‐based screening with real‐world data: Practical insights from diabetic retinopathy
Poschkamp, B., Kantz, L., Augstein, P., Tayar, A., Kaderali, L., Busch, M., Bohl, B., Paul, S., Lüdtke, L., Bründer, M., et al. (2025) · Acta ophthalmologica · doi:10.1111/aos.17591 · Cited by 4
Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes
Sasako, T., Ueki, K., Miyoshi, K., Miyake, K., Aoyama, T., Okazaki, Y., Ishizuka, N., Yamauchi, T., Noda, M., Kadowaki, T., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.3819 · Cited by 5
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
Zong, Y., Qiu, S., Zhang, H., Wu, J., Du, J., Kamoi, K., & Cen, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710376 · Cited by 4
Taha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Importance of the NHANES 2005-2008 Diabetic Retinopathy Data
Frank, R. N. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.125 · Cited by 4
Aljuaid, S. M., Alqahtani, R. A., Alqasem, S., Alsulaimani, Y. T., Alqahtani, S. A., & Alsalmi, S. K. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94096 · Cited by 4
Antwi‐Boasiako, C., Obeng, K. A., Amissah-Arthur, K. N., Musah, L., Abaidoo, B., Awuviri, H. W., Abbey, J. A., Awula, P., Tei, R. K., Agyemang, C. O., et al. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100139 · Cited by 4
Is there still a place for fenofibrate-statin combination therapy?
Farnier, M., Vrablı́k, M., & Catapano, A. L. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v2i3.55 · Cited by 4
Serum visfatin in patients with type two diabetic retinopathy
Salman, I. N., Mohammed, N. U. G., Atta, S. E., Abed, B. A., & Salim, R. (2024) · Diabetes Mellitus · doi:10.14341/dm13165 · Cited by 5
Current Treatment Options for Diabetic Retinal Disease
Bloomquist, R. F., Bloomquist, D. T., & Gardner, T. W. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0548 · Cited by 4
Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?
Handelsman, Y., Fonseca, V. A., & Rosenstock, J. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.73 · Cited by 4
Statins and Fibrates: Should They Be Recommended?
Chruściel, P., Mikhailidis, D. P., Toth, P. P., Rysz, J., & Banach, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_2 · Cited by 4
Blood Pressure Control in Type 2 Diabetes
Benck, U., Krüger, B., & Krämer, B. K. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1006411 · Cited by 4
Mohamed, Q. A., Fletcher, E. C., & Buckle, M. (2016) · Europe PMC (PubMed Central) · Cited by 4
Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy
Chai, Y., Liu, R., Yi, J., Ye, L.-H., Zou, J., Jiang, N., & Shao, Y. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.10.13 · Cited by 4
Managing Cardiovascular Complications in Diabetes
Betteridge, J. D., & Nicholls, S. J. (2014) · Wiley eBooks · doi:10.1002/9781118337967 · Cited by 5
Using secondary outcome to sharpen bounds for treatment harm rate in characterizing heterogeneity
Yin, Y., Cai, Z., & Zhou, X. (2018) · Biometrical Journal · doi:10.1002/bimj.201700049 · Cited by 4
Novel criteria to exclude the surrogate paradox and their optimalities
Yin, Y., Liu, L., Geng, Z., & Luo, P. (2019) · Scandinavian Journal of Statistics · doi:10.1111/sjos.12398 · Cited by 4
Kurosawa, T., Li, Y., Sudo, M., Haruta, H., Hagikura, K., Takayama, T., Hiro, T., Shiomi, M., Hao, H., Matsumoto, T., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01689-8 · Cited by 4
McKay, A. J., Gunn, L. H., Nugawela, M. D., Sathish, T., Majeed, A., Vamos, E. P., Molina, G., & Sivaprasad, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14344 · Cited by 4
Current Management of Diabetic Macular Edema
Okonkwo, O. N., Akanbi, T., & Agweye, C. T. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100157 · Cited by 6
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
